PET/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease

Andréa L Bastos, Gilda A Ferreira, Marcelo Mamede, Eliane V Mancuzo, Mauro M Teixeira, Flávia P S T Santos, Cid S Ferreira, Ricardo A Correa

ABSTRACT

Objective: To investigate the correlation of HRCT findings with pulmonary metabolic activity in the corresponding regions using 18F-FDG PET/CT and inflammatory markers in patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD).

Methods: This was a cross-sectional study involving 23 adult patients with SSc-associated ILD without other connective tissue diseases. The study also involved 18F-FDG PET/CT, HRCT, determination of serum chemokine levels, clinical data, and pulmonary function testing.

Results: In this cohort of patients with long-term disease (disease duration, 11.8 ± 8.7 years), a nonspecific interstitial pneumonia pattern was found in 19 (82.6%). Honeycombing areas had higher median standardized uptake values (1.95; p = 0.85). Serum levels of soluble tumor necrosis factor receptor 1, soluble tumor necrosis factor receptor 2, C-C motif chemokine ligand 2 (CCL2), and C-X-C motif chemokine ligand 10 were higher in SSc patients than in controls. Serum levels of CCL2 — a marker of fibroblast activity — were correlated with pure ground-glass opacity (GGO) areas on HRCT scans (p = 0.007). 18F-FDG PET/CT showed significant metabolic activity for all HRCT patterns. The correlation between serum CCL2 levels and GGO on HRCT scans suggests a central role of fibroblasts in these areas, adding new information towards the understanding of the mechanisms surrounding cellular and molecular elements and their expression on HRCT scans in patients with SSc-associated ILD.

Conclusions: 18F-FDG PET/CT appears to be unable to differentiate the intensity of metabolic activity across HRCT patterns in chronic SSc patients. The association between CCL2 and GGO might be related to fibroblast activity in these areas; however, upregulated CCL2 expression in the lung tissue of SSc patients should be investigated in order to gain a better understanding of this association.

Keywords: Tomography; Lung diseases, interstitial; Scleroderma, systemic; Cytokines.

INTRODUCTION

In patients with systemic sclerosis (SSc), interstitial lung disease (ILD) and pulmonary hypertension are the main causes of impaired quality of life and mortality. SSc-associated ILD involves autoantibody activity, inflammation, obstruction of small vessels, and tissue collagen deposition that further develops into fibrosis. It often occurs in diffuse cutaneous form and may take on varied expressions throughout its progression. A histological pattern of nonspecific interstitial pneumonia (NSIP) predominates, and usual interstitial pneumonia (UIP) and organizing pneumonia (OP) are seldom found. A newly described pattern of interstitial lung involvement is centrilobular fibrosis, which has been associated with chronic pulmonary aspiration through gastroesophageal reflux. Lung pathology is the gold standard method for an accurate classification of ILD. Open lung biopsy is an invasive procedure and is indicated in only a few cases because of its potential risks. Because of a strong correlation between a reticular pattern and fibrosis, HRCT has gained a central role in determining the nature of interstitial lung involvement, as well as in establishing referral criteria for biopsies and other procedures in selected cases. However, HRCT is less accurate in cases of ground-glass opacity (GGO) because this pattern may be related to both inflammation and interstitial fibrosis.

The literature reports on the usefulness of 18F-FDG PET/CT in the evaluation of non-neoplastic and connective tissue diseases, as well as pulmonary inflammatory conditions and pulmonary fibrotic conditions. For the evaluation of pulmonary metabolism, 18F-FDG PET/CT has the advantage of being a noninvasive technique and allowing quantitative assessment of the entire lung during image acquisition. However, radiation exposure

Correspondence to: Andréa Lima Bastos. Departamento de Anatomia e Imagem, Faculdade de Medicina, Universidade Federal de Minas Gerais, Avenida Prof. Alfredo Balena, 190, Sala 179, CEP 30130-100, Belo Horizonte, MG, Brasil. Tel.: 55 31 3409-9770. E-mail: andblima@yahoo.com.br

Financial support: None.

© 2022 Sociedade Brasileira de Pneumologia e Tisiologia

ISSN 1806-3756
should be taken into consideration. Although PET radiation exposure is mainly due to the incorporation of radiopharmaceuticals, the combined use of PET and HRCT may increase this exposure. However, in most cases the benefits (i.e., the information provided) outweigh the risks and justify the use of the method both in clinical practice and in research. In addition, radiation exposure should be optimized to a dose as low as reasonably achievable.

In SSc, the activation of macrophages and T cells in the bloodstream and tissues is responsible for the characteristic damage that occurs at the expense of the production of mediators that regulate inflammation and fibrosis. These mediators have been investigated as potential surrogates of inflammatory and fibrotic activity. (14) Inflammatory mediators that originate from various sources, such as the alveolar epithelium, macrophages, activated T lymphocytes, and the endothelium, are related to interstitial damage. (14,15) Soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis factor receptor 2 (sTNFR2), C-X-C motif chemokine ligand 8 (CXCL8), macrophage migration inhibitory factor (MIF), C-C motif chemokine ligand 2 (CCL2), C-X-C motif chemokine ligand 9 (CXCL9), and C-X-C motif chemokine ligand 10 (CXCL10) have been investigated. (15)

The objective of this study was to investigate the correlation of HRCT findings with pulmonary metabolic activity in the corresponding regions using 18F-FDG PET/CT and inflammatory markers in patients with SSc-associated ILD.

METHODS

This was a cross-sectional study conducted in the Pulmonology and Rheumatology Departments of the Federal University of Minas Gerais Hospital das Clínicas, located in the city of Belo Horizonte, Brazil. Adult SSc patients (> 18 years of age) with interstitial lung involvement on HRCT scans were recruited. The diagnosis of SSc-associated ILD was made in accordance with the 2013 American College of Rheumatology criteria. (16) The study was approved by the local research ethics committee, and all participants gave written informed consent. The exclusion criteria were as follows: overlapping of SSc with other connective tissue diseases, current or prior smoking, a diagnosis of occupational lung disease, acute or chronic infectious pulmonary disease, known exposure to toxic environmental antigens or toxic drugs, previous use of antineoplastic chemotherapy, pulse therapy with cyclophosphamide and/or methylprednisolone within six months of inclusion in the study, and HRCT signs suggestive of pulmonary aspiration. Serum levels of inflammatory mediators, clinical data, and lung function data were collected concurrently with the imaging examinations.

18F-FDG PET-CT and HRCT were performed with a PET/CT scanner (Discovery 690; GE Healthcare, Milwaukee, WI, USA) coupled to a 64-channel CT scanner (LightSpeed VCT; GE Healthcare). The study participants fasted for at least 6 h and were checked for blood glucose levels prior to intravenous administration of 3.7 MBq/kg (0.1 mCi/kg) of the radiopharmaceutical 18F-FDG. (11,12)

Approximately 50 min after 18F-FDG administration, HRCT was performed from the lung apex to the base in the supine position and for the duration of a maximal inspiratory apnea, the following parameters being used: slice thickness, 0.6 mm; voltage, 120 kV; and current, 200 mA. The data were reconstructed with specific algorithms for a lung and mediastinum study and evaluated with a window level of −700 HU and a window width of 1,200 HU for the lung, and a window level of 40 HU and a window width of 400 HU for the mediastinum. (18)

18F-FDG PET/CT images were acquired with a helical CT scanner from the skull to the thigh and with the use of a low-dose radiation protocol (voltage, 90 kV; and modulated current) to create an attenuation map and locate the anatomical regions of interest. This procedure was followed by the acquisition of molecular images in the corresponding regions; the images were acquired with the use of a 2-min acquisition time per bed position and were reconstructed in accordance with the manufacturer’s iterative protocol, with 24 subgroups and 4 iterations. (8,12)

Radiopharmaceutical uptake was defined as abnormal when it was higher than the mediastinal uptake. (6,12) This procedure was performed and interpreted by a senior nuclear medicine physician who was blinded to patient clinical status and the radiological patterns, and who used the maximum standardized uptake value corrected for lean body mass (SULmax) in the axial plane. The maximum values for each lung segment were recorded.

The baseline metabolic activity of the lung parenchyma was also estimated in normal regions on HRCT scans, being used in order to determine the background lung uptake and calculate the target-to-background ratio (TBR) as described by Groves et al. (10) To quantify the mean metabolic activity in each lung lobe, the volume of interest was visually assessed on the CT images by a thoracic radiologist, the mean standardized uptake value corrected for lean body mass (SULmean) being calculated using the PMOD software, version 3.609 (Bruker Corporation, Billerica, MA, USA).

The HRCT images were analyzed by two senior radiologists who have more than 20 years of experience in chest radiology and ILD diagnosis, and who were blinded to the results of 18F-FDG PET/CT. All images were read on dedicated workstations. Differences in opinion were decided by consensus among radiologists. The HRCT patterns of chronic interstitial pneumonia evaluated in the present study were NSIP, UIP, and OP. In addition, the presence of pure GGO (i.e., without concurrent interstitial lung abnormalities), honeycombing, GGO with fibrosis (a reticular pattern, bronchiectasis, or honeycombing),
and consolidation, as defined elsewhere,(17) was also analyzed. Segments without lesions were classified as normal. The reticular patterns were considered together with the other variables suggesting fibrosing disease because the participants had advanced-stage lung disease. The SULmax and SULmean for each lung lobe were compared to the HRCT patterns identified.

Pulmonary function tests were performed by a senior pulmonologist. The six-minute walk test was performed in accordance with international standards.(18) Lung volumes and DLCO were obtained with the use of a Collins system (Ferraris Respiratory, Louisville, CO, USA), and the results were reported as absolute numbers and percentages in relation to the predicted values for the Brazilian population.(19)

To determine the serum levels of inflammatory mediators, blood samples were collected from sex- and age-matched SSC patients and controls before performing PET/CT because reference values have yet to be established. Chemokines were quantified by sandwich ELISA in accordance with the manufacturer instructions (R&D Systems, Minneapolis, MN, USA). Serum levels of sTNFR1, sTNFR2, and MIF were also measured.(20) The inclusion criteria for controls were as follows: being over 18 years of age, having no chronic inflammatory disease, having no malignancy, having used no immunomodulators in the six weeks preceding blood sample collection, having undergone no surgery in the previous month, having suffered no extensive trauma in the previous month, having no history of kidney or liver failure, and reporting no current pregnancy.

To perform PET and CT studies, all patients underwent a wash-up period of at least 12 hours after a standardized meal. PET scans were performed using a Siemens Biograph mCT PET/CT scanner with 18F-FDG at 1 and 2.5 hours after injection. The uptake measurements were corrected for physical decay and attenuation. The SULmax and SULmean in lung lobes, the background SULmean, and the TBR were calculated as normal values.(21) Metabolic activity was analyzed by determining the SULmax and SULmean in lung lobes, the background lung uptake in normal areas, and the TBR. A total of 414 lung segments were analyzed, 140 (33.8%) of which had sufficient metabolic activity to allow SULmax measurements (Figure 1).

Median SULmean, SULmax, and TBR were 0.81 (0.44-1.69), 2.7 (1.50-5.30), and 4.91 (3.71-11.52), respectively. Interobserver agreement was 0.82.

To determine inflammation, blood samples were collected from sex- and age-matched SSC patients and controls. Chemokines were quantified by sandwich ELISA in accordance with the manufacturer instructions (R&D Systems, Minneapolis, MN, USA). Serum levels of sTNFR1, sTNFR2, and MIF were also measured.(20) The inclusion criteria for controls were as follows: being over 18 years of age, having no chronic inflammatory disease, having no malignancy, having used no immunomodulators in the six weeks preceding blood sample collection, having undergone no surgery in the previous month, having suffered no extensive trauma in the previous month, having no history of kidney or liver failure, and reporting no current pregnancy.

To perform PET and CT studies, all patients underwent a wash-up period of at least 12 hours after a standardized meal. PET scans were performed using a Siemens Biograph mCT PET/CT scanner with 18F-FDG at 1 and 2.5 hours after injection. The uptake measurements were corrected for physical decay and attenuation. The SULmax and SULmean in lung lobes, the background SULmean, and the TBR were calculated as normal values.(21) Metabolic activity was analyzed by determining the SULmax and SULmean in lung lobes, the background lung uptake in normal areas, and the TBR. A total of 414 lung segments were analyzed, 140 (33.8%) of which had sufficient metabolic activity to allow SULmax measurements (Figure 1).

Median SULmean, SULmax, and TBR were 0.81 (0.44-1.69), 2.7 (1.50-5.30), and 4.91 (3.71-11.52), respectively. Interobserver agreement was 0.82.

### RESULTS

Of the 27 patients screened between November of 2013 and November of 2014, 2 were excluded because of an exclusive small airway pattern on HRCT scans, 1 was excluded because of the development of neoplastic disease, and 1 was excluded because of the withdrawal of his consent. Therefore, 23 patients were enrolled. Of those, 78% were female, and the mean age was 47 years. The main clinical and lung function data are presented in Table 1. At enrollment, 6 patients were receiving prednisone therapy (mean dose, 8.7 ± 4.0 mg; range, 5.0-15.0 mg), another 6 were receiving treatment with azathioprine, and 5 were receiving treatment with methotrexate. The pulmonary function test results showed that 7 patients (30.4%) had normal TLC and 15 (65.1%) had abnormal lung function. Of those, 9 (39.1%) had restrictive lung disease, 5 (21.7%) had mixed restrictive and obstructive lung disease, and 1 (4.3%) had obstructive lung disease. One patient was unable to perform the maneuvers required to measure lung volumes.

### HRCT analysis

HRCT scans revealed a greater involvement of the lower lobes, with a predominance of GGO with bronchiectasis (90.0%), followed by pure GGO (65.4%). In addition, NSIP, UIP, and OP patterns were found in 19 (82.7%), 3 (13.0%), and 1 (4.3%) of the patients, respectively. Interobserver agreement was 0.82.

### 18F-FDG PET/CT analysis

Metabolic activity was analyzed by determining the SULmax and SULmean in lung lobes, the background lung uptake in normal areas, and the TBR. A total of 414 lung segments were analyzed, 140 (33.8%) of which had sufficient metabolic activity to allow SULmax measurements (Figure 1).

Median SULmean, SULmax, and TBR were 0.81 (0.44-1.69), 2.7 (1.50-5.30), and 4.91 (3.71-11.52), respectively. Interobserver agreement was 0.82.

### Table 1. Clinical and demographic characteristics of patients with systemic sclerosis (n = 23), as well as pulmonary function test results.*

| Characteristic         | Value               |
|------------------------|---------------------|
| Female sex             | 18 (78.0)           |
| Age, years             | 47.6 ± 12.5         |
| Duration of disease, years | 11.8 ± 8.7         |
| Limited form           | 09 (39.1)           |
| Diffuse form           | 14 (60.9)           |
| Raynaud’s phenomenon   | 21 (91.0)           |
| Digital ulcers         | 06 (28.0)           |
| Digital pitting scar   | 05 (24.0)           |
| Arthralgia/arthritis   | 14 (64.0)           |
| Pyrosis, dysphagia, diarrhea | 11 (48.0)         |
| Telangiectasia         | 04 (16.0)           |
| Cough and dyspnea      | 15 (65.0)           |
| TLC, L                 | 4.2 ± 0.7           |
| TLC, % predicted       | 87.4 ± 14.5         |
| FVC, % predicted       | 69.8 ± 17.6         |
| FEV1, L                | 2.0 ± 0.5           |
| FEV1, % predicted      | 69.5 ± 17.5         |
| FEV1/FVC               | 81.2 ± 5.4          |
| DLCO, %                | 64.7 ± 14.4         |
| 6MWD, meters           | 470.3 ± 72.5        |
| SpO2, %                | 88.7 ± 13.2         |

6MWD: six-minute walk distance. *Values expressed as n (%) or mean ± SD. **Clinical variables accumulated during disease progression.
respectively. The mean background lung uptake was 0.51 (0.083). Although 18F-FDG uptake values were highest for honeycombing, there were no significant differences in 18F-FDG uptake values between honeycombing and GGO. The correlations between HRCT patterns and 18F-FDG uptake values are shown in Table 2.

Of 13 lung lobes showing normal HRCT findings, 12 (92.3%) had no significant metabolic activity for the uptake measurement. In addition, the median SULmean (0.63) was similar to the baseline SULmax (0.51). There was no correlation between 18F-FDG uptake values and clinical and functional variables or concurrent therapy (data not shown). Furthermore, there was no difference between SULmean and SULmax values in patients with or without dyspnea (data not shown). There were no correlations between clinical or functional variables and 18F-FDG PET/CT findings, HRCT findings, or biomarker parameters.

**Inflammatory mediators**

Figure 2 shows a comparison of inflammatory mediators between the SSc-associated ILD group and the control group. Median serum concentrations of sTNFR1, sTNFR2, CCL2, and CXCL10 were significantly higher in the SSc-associated ILD group than in the control group. On the other hand, there were significant differences across HRCT patterns regarding serum levels of sTNFR2 (p = 0.017), CCL2 (p = 0.001), CXCL10 (p = 0.049), CXCL9 (p = 0.011), and MIF (p = 0.023; Figure 3).

In the multiple comparisons of these inflammatory mediators, the Mann-Whitney U test with Bonferroni correction was applied to the level of significance, which was set at 0.01. As can be seen in Figure 4, serum levels of CCL2 were significantly higher for GGO than for honeycombing (p = 0.007). Inflammatory markers and 18F-FDG uptake values were not significantly correlated. Disease duration had a moderate negative correlation with inflammatory mediators (p < 0.05).

**DISCUSSION**

The number of studies employing 18F-FDG PET/CT in the evaluation of ILD has recently increased. The present study involved patients with SSc-associated ILD and the use of 18F-FDG PET/CT. The results showed significant metabolic activity for all HRCT patterns. However, there was remarkable metabolic activity for honeycombing (an HRCT pattern that is frequently associated with fibrotic disease) and GGO. Furthermore, a correlation was found between GGO and serum CCL2 levels.

---

**Figure 1.** Low-dose CT and PET/CT scans of the chest showing honeycombing (in A), with scattered distribution of abnormal 18F-FDG uptake (in B), as well as ground-glass opacity (in C), with uniform distribution of abnormal 18F-FDG uptake (in D).
The GGO pattern is known as a marker of active or early-stage disease; however, the association between GGO and fibrotic disease in SSc was previously suggested by Shah et al., in a cohort of 41 patients undergoing serial HRCT examinations over a five-year period. The authors found that fibrosis progression was more common than lesion regression after treatment with D-penicillamine, cyclophosphamide, and prednisone; however, the association related to other diffuse pulmonary diseases. They found a mean SULmax of 2.8 and a predominance of GGO on HRCT scans.

Chen et al. demonstrated the sensitivity of 18F-FDG PET/CT in the assessment of acute pulmonary parenchymal inflammation. The authors evaluated the neutrophilic response induced by direct instillation of endotoxin into a lung segment in healthy individuals and showed that 18F-FDG PET/CT allowed quantification of the inflammatory response. Groves et al. studied pulmonary parenchymal metabolic activity in 36 patients with fibrosis, including idiopathic fibrosis with typical HRCT findings (18 patients) and fibrosis related to other diffuse pulmonary diseases. They found a mean SULmax of 2.8 and a predominance of activity in areas of honeycombing.

In the present study, PET was not useful for monitoring ILD in SSc patients because it failed to demonstrate significant differences between inflammatory activity and fibrotic areas, as suggested by findings of similar uptake for GGO and honeycombing images. However, if we take into consideration that SSc is a disease characterized by diffuse parenchymal involvement, the absence of significant 18F-FDG uptake in lung segments showing parenchymal lesions suggests that 18F-FDG PET/CT is useful in demonstrating the stability of the disease. Recently, three retrospective studies evaluated PET/CT scans of SSc patients under investigation for neoplastic disease, reporting that patients with progressing SSc-associated ILD had significantly higher pulmonary 18F-FDG uptake at baseline than did those with stable SSc-associated ILD. As demonstrated by Peelan et al., 18F-FDG PET/CT scanning might distinguish SSc-associated ILD patients from SSc patients without ILD because in their study SSc-associated ILD had significantly higher pulmonary 18F-FDG uptake than did SSc without ILD.

The quantification of 18F-FDG uptake in the lung parenchyma is challenging and highly dependent on breathing movements and signal from blood and water compartments. The ideal method for quantifying 18F-FDG lung uptake should exclusively reflect the metabolic activity in the lung cells to determine its pathogenic role. Although some methods have been tested, none was able to provide this information. Thus, comparison with clinical data is required in order to interpret PET quantification parameters correctly.

Not many studies have assessed the role of air and blood fraction correction vs. noncorrected images in 18F-FDG PET/CT examinations. Although we did not make these corrections, they have been reported to be important and the fact that we did not make them could explain why we did not find a clear relationship between 18F-FDG-PET signal and other measures.

Visual identification of small variations in 18F-FDG uptake in the lung parenchyma is often difficult, especially when there are highly heterogeneous parenchymal lesions. The TBR is a measure of the variation in 18F-FDG lung uptake. When next to 1, the TBR can indicate uniform 18F-FDG uptake, and a high TBR has recently been related to poor survival in idiopathic pulmonary fibrosis. In the present study, we found high TBRs in fibrosis and GGO patterns, especially for areas of active disease.

### Table 2. Comparison of median maximum standardized uptake value corrected for lean body mass, mean standardized uptake value corrected for lean body mass, and target-to-background ratio values with HRCT patterns in lung lobes.

| HRCT PATTERNS | Honeycombing (n = 16) | GGO (n = 28) | GGOOF (n = 53) | GGO (n = 28) |
|---------------|----------------------|--------------|----------------|--------------|
| SULmax        | 1.95 [0.0-3.8]       | 1.75 [0.0-3.8] | 1.79 [0.0-5.3] | 1.75 [0.0-3.8] |
| SULmean       | 0.92 [0.57-2.06]     | 3.4 [0.44-1.48] | 0.179 [0.35-1.67] | 0.77 [0.44-1.48] |
| TBR           | 4.0 [0.0-7.17]       | 0.0 [0.0-7.04] | 0.880 [0.0-11.52] | 3.6 [0.0-7.04] |
| **Normal**    | 0.0 [0.0-1.21]       | 1.75 [0.0-3.8] | 0.01 [0.0-1.21] | 0.0 [0.0-3.8] |
| SULmean       | 0.63 [0.46-0.76]     | 0.79 [0.44-1.48] | 0.001 [0.46-0.76] | 0.63 [0.0-7.04] |
| **Honeycombing** | 0.0 [0.0-2.57] | 0.0 [0.0-7.04] | 0.001 [0.0-2.57] | 0.0 [0.0-7.17] |

GGO: ground-glass opacity; GGOOF: ground-glass opacity with fibrosis (a reticular pattern, bronchiolitis, or honeycombing); SULmax: maximum standardized uptake value corrected for lean body mass; SULmean: mean standardized uptake value corrected for lean body mass; and TBR: target-to-background ratio. *Values expressed as median (min-max). *Mann-Whitney U test. Note: SULmax and TBR values equal to zero are related to regions without any qualitatively outstanding metabolic activity for measurement.
Figure 2. Comparative analysis of serum levels of inflammatory mediators in systemic sclerosis (SSc) patients (n = 23) and controls (n = 22). Mann-Whitney U test for determination of p values. sTNFR1: soluble tumor necrosis factor receptor 1; sTNFR2: soluble tumor necrosis factor receptor 2; CXCL8: C-X-C motif chemokine ligand 8; MIF: macrophage migration inhibitory factor; CCL2: C-C motif chemokine ligand 2; CXCL10: C-X-C motif chemokine ligand 10; and CXCL9: C-X-C motif chemokine ligand 9.

in areas of honeycombing (TBR, 4.02). Therefore, we considered it appropriate to add the $^{18}$F-FDG uptake value to that of the whole lung by determining the SULmean by volumetric segmentation of the lung lobes,
in addition to measuring the SULmax qualitatively in the areas of interest. \(^{(13)}\) The SULmax values are included in this volumetric analysis (SULmean), which results in much lower values.

The role of biomarkers in connective tissue disease-associated ILD was reviewed by Bonnela et al. \(^{(15)}\) Although the authors reported several correlations between increased levels of lung-derived proteins and chemokines and the presence or severity of ILD in these patients, they stated that they individually lack predictive value, and that disease prediction may depend mostly on combinatorial analysis of many of these mediators. \(^{(15)}\)

The inflammatory mediators whose serum levels were higher in the SSc-associated ILD patients than in the controls in the present study, i.e., sTNFR1, sTNFR2, CCL2, and CXCL10, are directly involved in the etiopathogenesis of SSc. Indeed, Hasegawa et al. reported that the levels of CXCL10, CXCL9, and CCL2 were higher in SSc patients than in controls, and that the variations in CCL2 over the three-year study period indicate skin and lung disease activity in SSc. \(^{(29)}\)

Regarding the association between cytokines and HRCT patterns, higher levels of CCL2 were observed when GGO predominated \((p = 0.007)\) (Mann-Whitney U test). This chemokine is known to stimulate inflammation and collagen production through fibroblast activation and inhibition of the production of prostaglandin E2 by alveolar epithelial cells, which in turn results in greater fibroblast proliferation, thus corroborating its important role in the genesis of fibrosis. \(^{(30-32)}\) Thus, the correlation between CCL2 and GGO may indicate a predominance of fibrotic activity.
REFERENCES

1. Perelas A, Silver RM, Arossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(9):304-320. https://doi.org/10.1016/S2213-2600(19)30480-9

2. Wells AU, Sten V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford). 2009;48 Suppl 3:i40-i44. https://doi.org/10.1093/rheumatology/kep109

3. Taylor JG, Bolster MB, Bronchiolitis obliterans with organizing pneumonia associated with scleroderma and scleroderma spectrum diseases. J Clin Rheumatol. 2003;9(4):239-245. https://doi.org/10.1097/01.rhu.0000083860.27509.f1

4. de Souza RB, Borges CT, Capelozzi VL, Parra ER, Jatene FB, Kavakama J, et al. Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. Respiration. 2009;77(4):389-397. https://doi.org/10.1159/000156958

5. Mathieson JR, Mayo JR, Staples CA, Müller NL. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology. 1989 Apr;171(1):111-6. https://doi.org/10.1148/radiology.171.1.2928513

6. Wells AU, Hansel DM, Corrin B, Harrison NK, Goldstraw P, Black CM, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992;47(8):738-742. https://doi.org/10.1136/thx.47.8.738

7. Wells AU. High-resolution computed tomography and scleroderma spectrum diseases. J Clin Rheumatol. 2003;9(4):239-245. https://doi.org/10.1097/01.rhu.0000083860.27509.f1

8. Nishiyama Y, Yamamoto Y, Dobashi H, Kameda T. Clinical value of 18F-FDG PET/CT, the contemporary collection of serum inflammatory mediators, and pulmonary function testing made the results suitable for the objectives of the study.

AUTHOR CONTRIBUTIONS
ALB, RAC, and GAP: study concept and design. ALB, RAC, GAP, MM, EVM, MT, FPSTS, and CSF: data analysis and interpretation. ALB, RAC, GAP, EVM, and MM: drafting and review of the manuscript for important intellectual content. All of the authors approved the final version of the manuscript.

CONFLICT OF INTEREST
None declared.
scanning in systemic sclerosis patients. Rheumatology (Oxford). 2020;59(6):1407-1415. https://doi.org/10.1093/rheumatology/kez483

22. Ledoult E, Morelle M, Soussan M, Ménkinian A, Béhal H, Sobanski V, et al. 18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Res Ther. 2021;23(1):76. https://doi.org/10.1186/s13075-021-02460-8

23. Bellando-Randone S, Tartarelli L, Cavaglì E, Tofani L, Bruni C, Lepri G, et al. 18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. Ann Rheum Dis. 2019;78(4):577-578. https://doi.org/10.1136/annrheumdis-2018-213376

24. Chen DL, Rosenbluth DB, Mintun MA, Schuster DP. FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J Appl Physiol (1985). 2006;100(5):1602-1609. https://doi.org/10.1152/japplphysiol.01429.2005

25. Chen DL, Cheriyan J, Chivers ER, Choudhury G, Coello C, Connell M, et al. Quantification of Lung PET Images: Challenges and Opportunities. J Nucl Med. 2017;58(2):195-197. https://doi.org/10.2967/jnumed.116.184796

26. Lambrou T, Groves AM, Erlendsson K, Screaton N, Endozo R, Win T, et al. The importance of correction for tissue fraction effects in lung PET: preliminary findings. Eur J Nucl Med Mol Imaging. 2011;38(2):201-207. https://doi.org/10.1007/s00259-011-1906-x

27. Schroeder T, Melo MF, Venegas JG. Analysis of 2-[Fluorine-18]Fluoro-2-deoxy-D-glucose uptake kinetics in PET studies of pulmonary inflammation. Acad Radiol. 2011;18(4):418-423. https://doi.org/10.1016/j.acra.2010.11.019

28. Chen DL, Mintun MA, Schuster DP. Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injury. J Nucl Med. 2004;45(9):1583-1590.

29. Win T, Screaton NJ, Porter JC, Ganeshan B, Maher TM, Fraioli F, et al. Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF). Eur J Nucl Med Mol Imaging. 2018;45(6):806-815. https://doi.org/10.1007/s00259-017-3917-8

30. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol. 2011;30(2):231-237. https://doi.org/10.1007/s10067-010-1610-4

31. Bandinelli F, Del Rosso A, Gabrielli A, et al. CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin Exp Rheumatol. 2012;30(2 Suppl 71):S44-S49.

32. Lindahl GE, Stock CJ, Shi-Wen X, Leoni P, Sestini P, Howat SL, et al. Microarray profiling reveals suppressed interferon-stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir Res. 2013;14(1):80. https://doi.org/10.1186/1465-9921-14-80

33. Bondue B, Sherer F, Van Simaey G, Dourmont G, Egrise D, Yakoub Y, et al. PET/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. J Nucl Med. 2015;56(1):127-132. https://doi.org/10.2967/jnumed.114.147421